Saturday, March 20, 2021

AMD disease | TED talk | Equity research | GRAY stock

 

Reversing Type 2 diabetes starts with ignoring the guidelines | Sarah Hallberg | TEDxPurdueU

Here is the link. I like to spend time to watch the video at least twice. 

Age-related macular degeneration, or AMD, is the leading cause of blindness in the developed world—and it has no cure. But recent advances in genetics have allowed a team of researchers in Australia to identify a kind of microRNA that could offer answers. In this fascinating talk, Dr Josh Chu-Tan explains the science behind their work, and shows how a new approach might unlock results that would otherwise be impossible. Joshua Chu-Tan is a postdoctoral fellow and lecturer in medical physiology and neuroscience at the Australian National University in Canberra, Australia. Josh’s research at the ANU’s John Curtin School of Medical Research focuses on the role of microRNA and their potential use as novel gene therapeutics for progressive retinal degenerations, with a specific focus on age-related macular degeneration (AMD), the leading cause of blindness in the developed world. His work in the field has been published in top-ranked ophthalmology and vision science journals and he also served as intern editor, blog writer, and advisor at world-leading academic publishing company, Springer Nature. Josh has earned numerous awards for conference presentations and public speaking events and competitions, including first prize at the Asia-Pacific 3 Minute Thesis, and A.T. Kearney Scholar/Finalist for Young Innovator of the Year at the prestigious Falling Walls Conference and Lab in Berlin, Germany. This talk was given at a TEDx event using the TED conference format but independently organized by a local community. Learn more at https://www.ted.com/tedx

GRAY stock




age-related macular degeneration | GRAY 800 shares | 5 bagger bet | I like to learn more about biotech | TEDTalk

March 20, 2021

Introduction

It is hard for me to organize a good research on equity research, GRAY stock, and I like to invest 5000 dollars and bet on 3 times return in next one or two years. I like to learn more about age-related macular degeneration disease. 

TEDTalk 

Reversing Type 2 diabetes starts with ignoring the guidelines | Sarah Hallberg | TEDxPurdueU

Here is the link. I like to spend time to watch the video at least twice. 

GRAY stock - my position 



AMD - age-related macular degeneration

Why I like to take risk to invest on biotech stocks, and I always rush to purchase stocks when biotech stock crashes. I like to make my investment as my learning experience, prepare myself to live and get most educated on challenges, one stock a time. I also like to make money by my research, good judegement, and hard working. 

Here are a list of stocks and biotech I learn:

  1. GRAY - AMD disease
  2. CRTX
  3. BLUE
  4. RUBY
  5. TBIO
  6. VIR
  7. TCDA
  8. ATNX
  9. IMVT
  10. SNGX
  11. GSK
  12. OTIC
  13. CVM
The diseases: 

breath cancer, kidney disease, hallucination etc. 


How good I am a researcher? | How good I am eager to make money in 54 year old? | What is poverty mindset? | My stock purchase review

March 20, 2021

Introduction

It is hard for me to understand how important it is my health. The value of health is so important, and I always worry about poverty and struggle to make good decision. I like to talk about $100,000 dollars my whole asset in cash and OVV.TO stock 97% price drop on march 27, 2020 and 500% rebound in less than 2 months. 

How good I am a researcher?

I could not find any issue related to my research on investment. I was too lazy and then spent whole 12 months after may 2019 to work on passive investment. After March 2020 stock market crash, I started again my first purchase on OVV.TO 300 shares. 

I just could not believe that my research was slow, I did not go back to try all kinds of ideas to invest and learn all businesses. It is hard for me to understand myself since I never image that I can be a millionaire, and then I have financial freedom to own a lot of things in my life. 

How good I am eager to make money in 54 year old? 

I do not know that I started to categorize myself to save one dollar in my grocery shopping. I am so happy to drive old used 21 year old Honda accord purchased in 2015. I did not seek so many ideas to make money. I just spent 12 months to work on research, weight control from 2016 to 2018, tennis sport research, and then I tried so hard to put together more than 500 hours to play tennis sports. 

I never challenge myself if I should seek ways to make more money. I can read very well, and I can use so many resources such as TFSA - tax free account in Canada. I only realized that I can have the account until 2019, TFSA started from 2016. 

I tried to be a nice person with Christian belief. But I did not do fully research to live a full life. I am happy to have a job, a small bedroom I can afford to rent. I have a two-bedroom condo for rent in Florida, and I only asked lowest price in the market price. 

My purchase of OVV.TO stock - price 97% drop - March 2020





Follow up 

March 25, 2021

After 12 month investment on stock market, I learned that I should have invested on OVV.TO at price $3.70 at least 10,000 shares since OVV.TO price dropped 97%, and then see what will happen next two months. 

I do believe that any unreasonable price drop like 97% on OVV.TO stock price definitely brought chance to make a fortune for a person to work on good research, good experience to invest on stocks consistently. I was sad to see that I was lack of wisdom and courage to invest even $10,000 Canadian dollars on OVV.TO on March 27, 2020. 

March 28 2021 stock purchase: GTE.TO 6600 shares | BORR 2000 shares | biotech stocks

 March 20, 2021



Scotia index fund portfolio: March 20, 2021 | Us Index fund | Canadian index fund

 March 20, 2021




Yahoo -> Finance -> Portfolio: Review my portfolios

 March 20, 2021

Introduction

It takes at least one hour to go over all portfolio I setup last year. It is learning experience to learn so many insights from reviewing those portfolios. I did make purchases of stocks last year, I like to learn better to manage my planning, execution and improve my research talent on equity research. 

Over 30 portfolios 




EDGAR | Company Filings | GTE stock

 March 20, 2021

I like to use this tool more often. Right now I have $5000 dollars to invest on GRAY stock 800 shares, and also GET.TO 6600 shares. 

Here is the link. 


2020 Sept. Canada oil stock portfolio | A beginner | Hold and invest long term

 March 20, 2021

Introduction

I am a beginner as a stock investor. I have to learn from my own mistakes, and learn how to discipline myself. If I can hold those oil stock positions and purchase more when the price is low after the purchase, the return will be much more. 

2020 Sept. Canada oil stocks

Those are my favorite oil stocks, SU.TO, IMO.TO, ENB.TO, HSE.TO, CVE.TO. 



What if 

What if I was smart enough to purchase 10,000 shares of OVV.TO on March 27, 2020, I also was able to hold those 10,000 shares to June, 2020 when it had 500% return? 

I may be able to take more risk on the stock market, and learn how to make huge return in less than 12 months. 

For me $10,000 Canadian dollars is huge amount, I have to save first 7 years from 2010 to 2017 in order for me to save $50,000 Canadian dollars. 

I have to learn the importance of investing, it is critical for me to learn how to catch the market down turn and also lowest price. 


IDRA stock: Idera Pharmaceuticals stock plunges after disappointing trial results, prompting analyst downgrade

March 20, 2021

Here is the article.

My highlights:

  1. IDRA, plummeted 63.3%
  2. melanoma - Google it, what kind of tumor?
  3. immunotherapy - find all immunotherapy companies
  4. 1.1 million share, spiked, 
  5. IBB - biotech ETF, comparison to IBB, overall performance
  6. I like to learn more from Yahoo -> Finance -> Conversation 

Shares of Idera Pharmaceuticals Inc. IDRA, -62.00% plummeted 63.3% in active trading to pace all premarket decliners, after the immunotherapy company said the ILLUMINATE-301 pivotal registration trial of its treatment of patients with anti-PD-1 refractory advanced melanoma failed to meet its primary endpoint of objective response rate. Trading volume spiked to 6.0 million shares ahead of the open, compared with the full-day average of about 1.1 million shares over the past 30 days. The company said it is evaluating its next steps regarding continuation of the trial, toward its endpoint of overall survival. "We are surprised and disappointed that the response data from ILLUMINATE-301 do not lead us to an accelerated path to a new and much-needed treatment option for these patients," said Chief Executive Vincent Milano. J.P. Morgan analyst Matthew Bannon followed by downgrading Idera to neutral from overweight, saying the trial results has led to "significantly more uncertainty on several fronts." Through Thursday, the stock had rallied 22.6% over the past three months, while the iShares Nasdaq Biotechnology ETF IBB, +1.70% has slipped 1.6% and the S&P 500 SPX, -0.06% has gained 5.6%.

Friday, March 19, 2021

NOK stock: 4500 shares | 22 thousand US dollars investment | 4.30 -> 3.90 price drop | VOO trend | Nasdaq 100 index

March 19, 2021

Introduction

It is so tough for me to manage the portfolio of $22,000 US capital on 4500 shares of NOK stock. My average cost is around $5.3 dollars, and I like to take time to learn how to make profit on this position. It takes courage, wisdom and hard working. 

VOO trend



Nasdaq 100 index


My position 


The idea I like to try is to determine the highest price around March 18, and then sell all 4500 shares, and then purchase back 4500 shares on price $3.97/ share. I need to check VOO ETF to determine the general trend. 


March 19 2021 | Ameritrade.com | IRA positions | GRAY stock 800 shares

 March 19, 2021




Thursday, March 18, 2021

GRAY stock: Wet macular degeneration

 Wet macular degeneration is a chronic eye disorder that causes blurred vision or a blind spot in your visual field. It's generally caused by abnormal blood vessels that leak fluid or blood into the macula (MAK-u-luh). The macula is in the part of the retina responsible for central vision.

Wet macular degeneration is one of two types of age-related macular degeneration. The other type — dry macular degeneration — is more common and less severe. The wet type always begins as the dry type.

Early detection and treatment of wet macular degeneration may help reduce vision loss and, in some instances, recover vision.

Wet Macular Degeneration
网络湿性黄斑变性;
[例句]The FDA approved Lucentis, an anti-angiogenic drug aimed at the blood vessels that cause wet macular degeneration, a leading cause of blindness.
该药作用于导致湿性黄斑变性的血管,而后者则是导致失明的一项主要原因。

Gray stock: 800 shares | average cost $8.3/ share | target price $15/ share

March 18, 2021

Introduction

I ran out of ideas to make profit on my TFSA account, so I came out the idea to try to work on 800 shares of investment on GRAY stock. I am not too greedy to get returns, I just like to assume that I have to hold it until the price goes up to $15/ share. 

More research

I like to take some notes from the article. 

  1. Goodman’s price target, which is reduced from $45 to $23
  2. the Phase 2b ALTISSIMO trial of GB-102
  3. the company’s twice-yearly intravitreal injection of sunitinib
  4. candidate for the treatment of wet age-related macular degeneration (wet AMD)


 Stocks go up, stocks go down, you can't explain that…

Or maybe you can, if the stock happens to be a biotech that just flunked a clinical trial. Which leads us nicely to Graybug Vision (GRAY). Or not so nicely if you happen to be an investor.

Shares cratered by a dispiriting 51% yesterday after the eye disease drug maker released preliminary data from the Phase 2b ALTISSIMO trial of GB-102 - the company’s twice-yearly intravitreal injection of sunitinib - and candidate for the treatment of wet age-related macular degeneration (wet AMD).

Investors were let down by a different set of data, which showed that the Best-corrected visual acuity (BCVA) of the 1mg GB-102 arm, came in 9 letters below the control arm of Eylea, Regeneron’s competing product.

On the plus side, after participants took 1mg of GB-102, the treatment displayed promising duration data with approximately 48% of patients staying treatment-free for over 6 months. Additionally, 62% of patients did not need any treatment for at least 4 months or more, with an overall median duration of 5 months. GB-102’s safety profile was favorable, too.

Despite being a secondary endpoint in the Phase 2b trial, BCVA is a major primary endpoint for registrational Phase 3 studies in wet AMD, and therefore, a potential key element in the treatment’s overall success.

Given that GB-102 showed very stable BCVA in the previous Phase 1/2 studies, Leerink analyst Marc Goodman considers the result a “negative surprise.”

“Management doesn’t have a good explanation for this result and will need to investigate this unexpected outcome further, but we are not surprised that the stock is off significantly, as investors are also clearly disappointed by the vision results,” Goodman said. “While we look forward to seeing additional granular data from the ALTISSIMO trial before making any changes to the numbers, we are lowering our POS [probability of success] today from 50% to 25%.”

The disappointing data also results in a cut to Goodman’s price target, which is reduced from $45 to $23. Despite the severe haircut, the figure still represents possible upside of a hefty 210%. To this end, Goodman’s rating stays an Outperform (i.e. Buy). (To watch Goodman’s track record, click here)

Since the data was published, other Street analysts have been less forgiving, with several downgrading the stock’s rating. Nevertheless, based on 3 Buys and 2 Holds, the stock still boasts a Moderate Buy consensus rating, backed by a bullish $19.60 average price target. Gains of ~165% could be in the cards, should the target be met over the next 12 months. (See GRAY stock analysis on TipRanks)

To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.

Gray stock: 800 shares | Expect 5 time return | Market for retinal disease | Prepare for retirement | Yahoo finance -> conversation

 March 18, 2021

Introduction

I made quick decision to invest 800 shares of Gray stock since I think that it may be a good candidate to bring 5 times return in short future or a few years. I like to learn more about vision and health of eye. I like to push myself to learn how to be a good investor on Gray stock as well. 

Gray stock -> Yahoo -> Finance -> Conversation

I do not have knowledge to do research on gray stock, so I just copy some comments from Yahoo -> Finance. I bought 800 shares of GRAY stock with average price $8.30/ share. 

Highlights - 500% 

GrayBug - For people with chronic diseases of the retina and the optic nerve, we develop medicines that make healthy vision more accessible and manageable, promoting better compliance and visual outcomes.

Look at $eyes- they are in similar business, stock is up 500%. Soon $gray is going to fly. Get in

ACRX stock

market not liking the GRAY Ph 2b results, still think upside!!!!!!!!!!!! buy the dip!!! also, look at ACRX climb! very BULLISH ACRX article out this morning - read it!
ACRX 550% upside!

$GRAY
Initiates Coverage On Needham & Company LLC Buy USD 30
Initiated by Piper Sandler Overweight USD 27
Initiates Coverage On Wedbush Outperform USD 41
Initiates Coverage On SVB Leerink Outperform USD 35

Phase 2 trial 

The selloff was intended. Big investors will buy, buy and hold, this is a good pharma stock, and retina solutions are being on fire lately, good sector, good phase 2 trial... I don't understand this overreaction that is not proportional to the actual facts. It should have been the opposite +50% after the report and not this massive selloff. I feel something big is going to happen be prepared. Shouldn't be surprised to see the stock again at 15-17$ tomorrow.

As of today, 22 patients have successfully completed 2 months or more of this six-month extension period without the need for further treatment. No averse effects and sustained benefit. THIS IS GOOD NEWS!!!


Actionable Items

This research is new to me. I have no idea that I should invest $5000 dollars on this GRAY stock. I do think that vision is so important and it is a big market to advance research and development a product for patients. 


Follow up 

June 16, 2023

I have to learn how to work on equity research in the right way. What is the right way? 

Feb. 23, 2024

I need to get professional help, subscribe Morningstar, seekingalpha, IBD digital, and also start to read books about investing. 

I should start to read investing books early, and practice trading stocks, and look into my problems. 

2025 July 02

I should look into GRAY trades again starting from 2021, and write down lessons I should have learned. 

#GrayStock #TradeLessons #Trade2021 #BigGamble #bigLoss #WhatToLearn #MarkMinervinie #RiskManagement #StopLoss #PennyStock #Trading #BusinessEducation 

Gray stock: 800 shares | Expect 5 time return | Market for retinal disease | Prepare for retirement | Yahoo finance -> conversation | Naive trader | Big Loser 

Learn how to discipline | Find a trade | Stock | How to do technical analysis for a trade | GRAY stock 


Tennis sports: Tennis Footwork Workout At Home (No Equipment)

March 18, 2021

Here is the workout I like to work on daily. Here is the link. 

Tennis sports | 200 lb | 20lb weight loss plan | workout | workout for tennis players

 March 18, 2021

Introduction

It is hard for me to have good weight control. I have weight control issues. I have to push myself to learn again in 55 year old. I have to go back to tennis sports and learn how to work on my daily routines inside home. 

Tennis workout

Here is the video. I like to practice this workout every day at least 10 times. I like to learn basic stretches. 

25-Min Workout for Tennis Players | Level 1 w/ Brent Bishop

TBIO stock: 100 share purchase | 30% market price drop | 30 minutes research

Yahoo -> Finance -> Conversation 

There are only 5 major mRNA companies on the market. Two that lead the sector, MRNA and BNTX, then there is CVAC, and then we have ARCT and TBIO. MRNA technology is going to revolutionize medicine, and this company is practically a small cap, so its potential upside is huge in the long term. The absence of catalysts may erode the price during this year, if this were the case, it would be an opportunity to buy (new or more). I think it cannot be ruled out that Sanofi will buy this company this year or next before it becomes very expensive. Sanofi paid $ 23 for its TBIO shares.

Tastytrade: Trade Checklist | Jade Lizard

 March 18, 2021

Here is the link. 

The jade lizard is a neutral to bullish strategy that takes advantage of volatility skew. Mike breaks down everything you need to know about the strategy, and offers a few tastytrade tips for trade entry!



TBIO stock: 100 share | 30% loss | First time buyer

March 18, 2021

Here is the article. 

Translate Bio Plummets On Unexpected Testing Flop For mRNA Drug

Translate Bio (TBIO) could be facing a two-year delay for its cystic fibrosis drug, an analyst said Thursday as TBIO stock crashed on an unexpected testing flop.

The company said its inhaled cystic fibrosis treatment proved safe in testing, but failed to improve lung function. The drug uses the same messenger RNA technology that powers highly effective coronavirus vaccines from Pfizer (PFE) and Moderna (MRNA).

On today's stock market, TBIO stock plunged 30.9% to 17.76.


BORR, GTE.TO stock: Oil Falls By Most in 6 Months as Recovery Falters, Dollar Gains

March 18, 2021

Introduction

I had strong allergy about pollen, so I stayed at home. I made purchase of 6000 shares of GTE.TO stocks and 2000 shares of BORR. I like to look into Crude oil price drop. 

Crude oil

Here is the article.  

Oil plunged by more than 6% to the lowest since September as vaccination efforts in some parts of the world stalled, casting uncertainty over the speed of an economic recovery and a full rebound in global oil demand.

West Texas Intermediate crude futures are headed for the longest stretch of daily losses in more than a year. China lifting less crude and U.S. Gulf Coast refineries still recovering from a cold blast last month have put short-term pressure on physical oil demand. Meanwhile, some efforts to distribute Covid-19 vaccines have faltered and a stronger dollar is reducing the appeal of commodities priced in the currency.

The collapse in prices has wiped out two weeks worth of gains for the U.S. benchmark crude and represents a setback for a market that has otherwise staged a remarkable recovery since the depths of the pandemic. Oil futures are still up well over 20% since the start of the year with the world’s largest oil producers reining in supply and travel around the world recovering post-lockdowns.

“Short-term supply and demand considerations are temporarily casting a shadow over the bright future that is likely to arrive in the third quarter of the year,” said Tamas Varga, an analyst at PVM Oil Associates Ltd.

Oil’s move lower may also be linked to some unwinding of long positions by commodity trading advisors as daily price gains or losses of more than 3% can often trigger funds to quickly unload. “This is a risk-off moment with some of the cyclical trades,” said Rob Haworth, senior investment strategist at U.S. Bank Wealth Management.

Beyond headline prices, crude’s closest timespreads are signaling that, despite the outlook for a longer-term recovery, near-term demand remains fragile. WTI’s front-month contract is trading at a discount again to the following month, while Brent’s backwardation -- a bullish structure signaling tighter supplies -- is weakening.

Wednesday, March 17, 2021

Learning ability | growth mindset | Stock investment | pump and dump | short sales squeeze | long term investment

 March 17, 2021

Introduction

It is best time for me to learn how to invest on stock market. I am also looking into the research topics related to learning ability, growth mindset, and also techniques in terms of stock investment. 

Learning ability

I did start to learn and make some gains on my Ameritrade.com IRA account. I also took seriously on my unrealized loss on NOK positions 1500 share. I chose not to sell for loss, and invest on NOKIA as a business, and support the business to grow. 

Growth mindset

I also learn  how to work with greedy, and try to make small profit one a time. In the same time, I learn to work on equity research comparison between AT & T and Boeing from January to March 17, 2021. 


ACAD stock: 100 shares investment - how to invest better?

 March 17, 2021

The article is here. 

Here are highlights:

  1. Nuplazid - 2 billion in incremental sales
  2. ACAD stock - analyst average estimate stands at $44
  3. 60% premium to the current stock price of $27. 
  4. Nuplazid is already approved for hallucinations and delusions related to Parkinson's disease, while the current trial was for patients with hallucinations and delusions due to demontia-related psychosis. 

ACADIA Pharmaceuticals Stock Now Looks Oversold At $27 Levels

We believe that ACADIA Pharmaceuticals stock (NASDAQ: ACAD), a biopharmaceutical company focused on neuroscience drugs, is a good buying opportunity at the present time. ACAD stock trades near $27 currently and it is, in fact, down 43% from its pre-Covid high of around $47 in February 2020 – before the coronavirus pandemic hit the world. ACAD stock has had a volatile ride the past few months. It rallied from levels of under $35 in March 2020, when broader markets made the bottom, to levels north of $50 in late February 2021. However, over the recent weeks, the stock has plummeted to levels of $27 currently. The recent drop can be attributed to the U.S. FDA finding deficiencies in its application for its psychosis drug – Nuplazid. This is an important update given that Nuplazid sales with the new approval were touted to add as much as $2 billion in incremental sales. At the current price of $27, ACAD stock is actually trading below the levels seen in March 2020, while the broader S&P500 Index has rallied 77% over the same period.

However, the selling now appears to be overdone. After the recent development many analysts cut their price targets for ACAD stock, but still the average price estimate stands at $44, implying a potential 60% premium to the current stock price of $27. Furthermore, the company has stated that it will work with the U.S. FDA to resolve the discrepancies in its application. It should be noted that Nuplazid is already approved for hallucinations and delusions related to Parkinson’s disease, while the current trial was for patients with hallucinations and delusions due to dementia-related psychosis. Any hopes of approval in this space will be a positive for the company. In this note we focus on a comparative analysis of ACADIA Pharmaceuticals stock performance during the current financial crisis with that during the 2008 recession in our interactive dashboard.

Tuesday, March 16, 2021

TD Ameritrade | IRA | Positions | realized gains | unrealized gains | March 16, 2021

 March 16, 2021




Actionable Items

  1. Do not be too greedy. Take profit of $180 ACAD position this morning, and then buy back when the price was 3 dollars less. That is $500 dollars difference. 
  2. Sell ATNX for profit $150 dollars, and purchase back when the price is lower. 
  3. Do not think too much
  4. Keep going to work on reading but work on positions to sell for gains. 

Finviz.com | Gainers | Losers | Volume

 March 16, 2021





RUBY stock: Rubius Stock Flies To Record High After Experimental Cancer Drug Proves Itself

March 16, 2021

Here is the article. 

An experimental cancer treatment from Rubius Therapeutics (RUBY) showed early promise on Monday, leading RUBY stock to nearly double.

On the stock market today, RUBY stock skyrocketed 84.4% to 30.29.

The company tested its drug, known as RTX-240, in patients with solid tumors. The treatment led to partial responses in two patients — one with metastatic anal cancer and one with melanoma of the eye. Researchers deemed six other patients stable.

Chief Executive Pablo Cagnoni says he believes the results provide clinical validation of the company's technology. Rubius tests include cancer treatments using red blood cells engineered to mimic the immune system.

"The encouraging safety results, including a single event of Grade 1 liver toxicity, and preliminary (effectiveness) data for RTX-240 to date give us the potential to realize the power of immune agonists for the treatment of cancer," he said in a written statement.

RUBY Stock Skyrockets

The results stoked RUBY stock to a record high.

Tumors shrank by 54% in one patient with metastatic anal cancer. A patient with melanoma of the eye also had cancerous lesions on the liver. The targeted lesion completely disappeared.

Both patients had previously worsened while receiving immunotherapy drugs that target the protein PD-1. Treatment with RTX-240 was still ongoing eight and four months after the data cutoff for the studies in anal cancer and melanoma, respectively.

Also bullish for RUBY stock, six other patients were considered stable following treatment. Four of those were stable for at least 12 weeks, Rubius said. Those patients had cancers of the lungs, soft tissue, pancreas and prostate.

The most common treatment-related side effects included fatigue, nausea, decreased appetite and joint pain. Five of the patients experienced immune-related side effects. More serious adverse events included inflammation of lung tissue, insufficient levels of a specific hormone and hypothyroidism.



Monday, March 15, 2021

Gray stock: My research starts from 800 shares of investment on March 15, 2021

March 15, 2021

Graybug Vision (GRAY)

Last on Needham’s value list is Graybug, a biopharmaceutical firm conducting clinical-stage research on medications to treat chronic diseases of the retina and optic nerve. The company focuses on long-term treatments, with drugs to be administered no more than twice per year – and provide relief from vision loss due to age-related macular degeneration and diabetic macular edema.

Graybug’s IPO in September was notably successful; the company started trading at $16 per share, above the $15 originally planned, and sold almost 1 million more shares than first announced.

Biotech firms are famously mercurial as stock investments. They tend to run deep losses for long periods, as medical research is both expensive and impossible to short cut. The rewards, however, are real, as one popular drug, or a treatment that is perceived as essential, can bring in tremendous profits once it goes on the market. That’s the value Needham sees here.

Starting coverage on this stock for Needham is analyst Serge Belanger, who says of GRAY, “Anti-VEGF therapies generate ~$12B in WW sales as the standard of care for retinal diseases despite 40%-50% of patients experiencing inadequate responses and a treatment burden that impacts patient compliance. We believe [the company's] GB-102 can disrupt the anti-VEGF market with a differentiated mechanism of action and longer-dosing intervals. Upcoming ph 2b trial data in 1H21 represent the most near-term value-driving catalyst.”

In line with his outlook, Belanger rates the stock a Buy. His $30 price target represents an impressive 96% upside potential for the year ahead. (To watch Belanger’s track record, click here)

Wall Street agrees that GRAY is a buying proposition. The stock has 6 recent reviews, and all are Buys, making the Strong Buy consensus rating unanimous. Shares are selling for $15.32, and the $32.50 average price target implies an upside of 115%. (See GRAY stock analysis on TipRanks)


Actionable Items


I like to work on investment with potential 300% return in next year or two. So I chose to invest on (Grayview bug)(should be: Graybug vision) inc stock GRAY. 


March 15 2021: Finviz -> Screener -> top gainers/ losers/ volume

 March 15, 2021





I cried last weekend | Love your neighbor as yourself Mark 12:31

 March 15, 2021

Introduction

It is hard to read the news from my classmate and his passaway, and I also had to learn the fact that he fight so hard to  the cancer even if the cancer was already spreaded to spine, causing paralysis. I had time to cry and also reviewed several things related to my classmate.

Love your neighbor as yourself - Mark 12:31

I chose to stay in a small wechat group, but I also learned the hard time to deal with coldness. How to build a good community around myself. I thought about in 2008 I went to Shenzhen city, stayed in my elder sister's home. My sister advised me to contact old classmates. I did contact one, who was my friend and classmate in high school, and same city in Shanghai from 1984 to 1988. I did not have chance to visit the city of Guangzhou. I did not visit any of my classmates during my trip to Shenzhen, and Hongkong airport back to USA. I felt so cold to live in the city of ShenZhen. I visited the theme park in the city of Shenzhen called window of world.

I did stop by San Francisco and my ex-roommate back in 2001 welcomed me to stay at her house, and we got together in a restaurant, and she drove me to visit Google headquarter and also Yahoo center in Silicon Valley. 

I like to remind myself bible teaching: Love your neighbor as yourself. I spent half hour to clean my desk, and then set my desktop background image. I like to live my life to full. 








Finviz -> Screener -> Change | gains | losses | volume

 March 15, 2021





Sunday, March 14, 2021

Equity research: learning experience from T stock to BA stock

 March 14, 2021

Introduction

It was my first equity research on AT & T stock during pandemic, and then after careful consideration, I made purchase of 800 shares of T stock in Jan. 13, 2021. Now I had chance to compare to my close friend in JTU investment wechat group. The different huge gap between two stocks: T and BA. I like to spend hours to look into BA stock this Sunday. 

T stock and BA stock 


Comparison to BA stock

BA stock share price went up more than 30% from Jan. 13, 2021 to March 14, 2021


If I could have made good choice to compare T with other biggest companies like BA, then I may choose to invest half of them to BA stock. Then I should have 30% return on BA stock, 9000 dollars capital will bring me $2700 dollars profit. 

Knowledge is power. I should have spent more on a few more stocks. Boeing is such a great company and it is so easy to understand since there are so many articles and youtube.com videos as well. 




BA stock: Did Boeing just turn a major corner? Here's the news that sent shares soaring today

March 14, 2021

Here is the link. 

Airline in the world - 

Meet NASA Astronaut & Artemis Team Member Jonny Kim [Video]

 March 14, 2021

I had hard time to grow up. I am lack of a lot of things. Biggest lack is lack of confidence. - grow up - 

Here is the link. 

NASA astronaut Jonny Kim is a member of the Artemis Team, a select group of astronauts charged with focusing on the development and training efforts for early Artemis missions.

Dr. Jonny Kim was selected by NASA to join the 2017 Astronaut Candidate Class. He reported for duty in August 2017 and completed two years of training as an Astronaut Candidate. A U.S. Navy SEAL, Kim completed more than 100 combat operations and is the recipient of the Silver Star and Bronze Star with Combat “V”. Kim was commissioned as a naval officer through an enlisted-to-officer program and earned his degree in mathematics at the University of San Diego and a doctorate of medicine at Harvard Medical School.

Kim enlisted in the Navy as a Seaman recruit after graduating high school in 2002. After completion of Hospital Corpsman “A” school training, he reported to Basic Underwater Demolition/SEAL (BUD/S) training in Coronado, CA. After completing his training at Naval Special Warfare, Kim reported to John F. Kennedy Special Warfare Center and School in Fort Bragg, NC for the Special Operations Combat Medic Course. He was assigned as a Special Warfare Operator to SEAL Team THREE Charlie Platoon in San Diego, California and obtained various qualifications including Military Freefall Parachutist, Combatant Diver (closed circuit rebreather), Naval Special Warfare Special Reconnaissance Scout and Sniper, and Advanced Special Operations Techniques.

Here is the video link. 


Jason Liu | Facebook recruiter | AI

March 14, 2021

I like to spend at least 10 minutes to go over the linkedin page of Jason Liu. 



Hands-on Algorithmic Problem Solving | Book reading | Li Yin | github | algorithm expert

March 14, 2021

Here is the link. 

I am planning to spend at least 10 hours to go over those algorithms, and then take my notes. 


Saturday, March 13, 2021

Investment: It is to be humble, learn from the best

 March 13, 2021

Introduction

I put together a wechat investment group for JTU alumni. My friend Fu is the first one to reach out to me. I have chance to learn from her and her positions. She made 250% return in last 52 weeks. 

BA, SAVE stocks